USTR Says Stance On Drug Patents 'Flexible' In TPP Talks

Law360, New York (November 27, 2013, 3:17 PM EST) -- The U.S. Trade Representative's office said Wednesday it will seek a “flexible” approach to pharmaceutical intellectual property provisions in the Trans-Pacific Partnership, attempting to allow access to lifesaving medicine while also retaining incentives for new drugs to be developed.

In a blog post, the USTR's office provided details on its negotiating approach across several of the intellectual property provisions that are likely to be included in the TPP, a proposed trade agreement between the U.S. and 11 other Pacific Rim countries. The office said, in general,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.